Physician profile
Geoffrey Cronen
NPI 1124059332
$2,159,685.00
in general payments reported to CMS, 2019-2025
6 companies · $550K in 2025
The $550K reported for 2025 was more than what 99% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $131K · 2021: $207K · 2022: $306K · 2023: $424K · 2024: $495K · 2025: $550K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.4M · Consulting Fee: $13K · Travel and Lodging: $6,990 · Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,446,944.06 |
| Consulting Fee | $13,375.00 |
| Travel and Lodging | $6,989.61 |
| Food and Beverage | $394.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $2,159,265.02 | 2019-2025 | Invictus Open, Other - Miscellaneous, Invictus Vise |
| Stryker Corporation | $110.69 | 2019-2021 | |
| Globus Medical, INC. | $100.78 | 2022 | |
| Smith+Nephew, INC. | $85.03 | 2022-2025 | Coblation, Rf20000, Pico 14 |
| Endo Pharmaceuticals INC. | $81.05 | 2020-2022 | |
| Polynovo North America LLC | $42.43 | 2024 | Novosorb Btm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Cronen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.